Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

September 30, 2026

Dana-Farber

1

The FDA has approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy.
2

Daraxonrasib is an oral multi-selective RAS(ON) inhibitor.
3

The approval is based on the RASolute 302 trial comparing daraxonrasib to chemotherapy.
4

The RASolute 302 trial was led by Brian Wolpin, MD, MPH, at Dana-Farber Cancer Institute.
5

Daraxonrasib is indicated for patients not candidates for multiagent systemic therapy.

Original Source(s)

Dana-Farber

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

September 30, 2026

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

1

2

3

4

5

Original Source(s)

Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field

Related Content

Association of Adjuvant Radiotherapy De-Escalation With Outcomes Following Oncoplastic Breast-Conserving Surgery

Late enhancement and washout maps for distinguishing tumor progression from radiation necrosis in malignant brain tumors: an exploratory study

Screening strategies for the early detection of non-cardia gastric cancer in low- to moderate-prevalence regions: Asia-Pacific gastroesophageal cancer congress consensus 2026